Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Algernon NeuroScience reports successful 2nd Cohort dosing in DMT clinical study
Outstanding: 114,144,104 for April 5, 2023
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_April_5_2023.pdf?9x35wGkRRA353UHuAMvPjbsQoniVdOxg
Bell Buckle (OTC: BLLB) Terminates VRL Agreement
https://www.otcmarkets.com/stock/BLLB/news/Bell-Buckle-OTC-BLLB-Terminates-VRL-Agreement?id=395497
Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-Announces-Successful-Dosing-of-2nd-Cohort-in-Phase-1-DMT-Clinical-Study?id=395593
Yeah we’ve been here a long time and why ?
Only Stock for us to Trade or Invest into make Money, OTC Market is all about Companies using Stock to gather $CASH to do what the Company said they were doing. Traders as us Hop•On or Hop•Off hoping to make a Profit or @ least a good loss for the Year, if you can see the Stock falling further down and grab maybe double of 50% or even 25% more share hold.
I for one as you see I believe this finally happening here.
Here’s some more thought of mine, JMO
Warren County Pennsylvania started another device that actually does what a Trained Officer does watching Eye’s but a device that does way better than any Officer can do, this will tell you if they are impaired — $BLO once $BLOZF gonna say been in the last few hours you have Cannabis and the right kind that get you high, this new GAIZE device says you Impaired and $BLOZF gonna $BLO gonna say if it’s THC or does the Officer need to have them blow a BAC Breathalyzer, $BLOZF already has a Breath Capture device at the Time of Blowing a $BLOZF and if the instant read technology says there THC within 3 Hrs, it keep the Sample to run without doing anything but hook it to the FAIMS back at the station
Warren County law enforcement is adding to its options for determining if drivers are impaired by marijuana.
On Thursday, District Attorney Rob Greene announced that the county is piloting the Gaize VR goggles rapid screening device.
Warren County law enforcement is adding to its options for determining if drivers are impaired by marijuana.
On Thursday, District Attorney Rob Greene announced that the county is piloting the Gaize VR goggles rapid screening device.
https://www.post-journal.com/news/community/2023/04/county-using-cannabis-impairment-detection-tech/
Watch Video
We’re in Court so•to•speak & waiting the outcome
Interim Financial Statements
https://webfiles.thecse.com/Cannabix_FS_Jan_31_2023.pdf?a6YQN8zDFJfTiqx97PLL_r6.5xAP9fcy
Balance, January 31, 2023
Cash and cash equivalents $6,941,288
JMO - Their burning up less than $1.5M Yr
So roughly 4 to 5 Yrs if no Product to help generate $Cash — but — “JMO” — $BLOZF gonna $BLO before then
Paid #OTC IQ app fee again!! Hopefully won't request any additional docs. Then we can file the financials. FINALLY!! #lfg $medh
— the 1 & Only HANS (@The1OnlyHans) March 28, 2023
DATE • SHORT INTEREST • % CHANGE
03/15/2023 3,760 -83.13
02/28/2023 22,282 10.33
02/15/2023 20,196 35.45
01/31/2023 14,910 574.97
01/13/2023 2,209 10.45
12/30/2022 2,000 -78.54
12/15/2022 9,321 -56.07
11/30/2022 21,218 -31.29
11/15/2022 30,880 80.04
10/31/2022 17,152 -72.56
https://www.otcmarkets.com/stock/BLOZF/quote
JMO — $BLOZF Gonna $BLO
Biggest % Drop and short is Bought Back
SHORT INTEREST means nothing to us Traders other than a sign, look as to how many shares - less than 4,000 and @ .25 on price now is like $1,000 bucks but they also Buying up any @ these levels and waiting the Run to sell more SHORT INTEREST once they Jack the Price Up by Buying this .25 Price and run it
Gonna be a THC Breathalyzer
Who else sell shares in a THC Breathalyzer?
1st Bid for AGN.RT (Bidder for 15,000 rights on CSE)
.05 CAD is .037 USD
Right gives you share @ .25 $AGN or if could be bought in the USA for .18 $AGNPF
Making then after buying the right and the Unit which is 1 share and 1 right to the Warrant for .52 $AGN — converted is .217 $AGNPF but you have to buy on the CSE exchange for a total of .30 $AGN
P.S. — None have sold and there is no Ask yet —> Only someone wanting to Buy you USA Right that could have been GAVE to YOU if not in the USA (I think at least it should be null and void the Number of Shares held in the USA exchange)
GAVE to Holders in CSE Exchange, and USA holders of $AGNPF will be sold by Broker
So Rights are Free to CSE and not making a dime for Company and that’s why this deal is to raise Money as they have none to even pay last Quarter let alone and move forward
Another look is 4/1 forward split for any holder holding a share and then the CSE holders get another 4/1 kinda by GIVING you rights 1/1 to sell or buy the Unit for .18 $AGNPF price
https://thecse.com/en/listings/life-sciences/algernon-pharmaceuticals-inc-27april2023-rights
My Opinion — USA holders of $AGNPF are screwed again
To have Rights you need $AGN in your Holdings and not $AGNPF
Rights of $AGNPF will be given to the Broker to sell your Rights (Which are Free to holders of $AGN and Right gives you .25 CAD which is .18 $AGNPF shares)
But all Rights probably will gout the door meaning 19,307,312 will be the Outstanding and maybe 28,960,968 if Warrants for .38 $AGNPF go
Rights will trade like warrants kinda, owning the Right to a .18 $AGNPF share and then a Warrant on top of that. you can buy that Warrant for .38 $AGNPF
JMO on $AGNPF Holders
But you need to Trade on CSE not OTC
I own no shares but do have a Sister who is a die-hard and waiting for roughly $6 $AGNPF
I think the time is less than a month away
JMO
Algernon Pharmaceuticals Announces Launch of Rights Offering
VANCOUVER, BC – (March 21, 2023) – Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”). The Company will be offering 9,666,988 rights (the “Rights”) to holders (the “Shareholders”) of its Class A common shares (the “Shares”) at the close of business on the record date of March 29, 2023 (the “Record Date”) on the basis of one (1) Right for each one (1) Share held. Each one (1) Right will entitle the holder to subscribe for one unit (a “Unit”) at the subscription price of $0.25 per Unit.
Each Unit will consist of one Share and one Share purchase warrant (a “Warrant”), with each Warrant being exercisable for one Share at the exercise price of $0.52 for a period of 18 months after the date of issue of the Warrants, subject to acceleration to a date that is not less than 30 days following delivery of an acceleration notice to the holders of the Warrants if the volume weighted average price of the Shares for each of the ten consecutive trading days on the Canadian Securities Exchange (the “CSE”) exceeds $1.04. Pricing of the Rights Offering is mandated by applicable Canadian securities law and the policies of the CSE which require the Company to offer existing Shareholders a significant discount to purchase new securities in order to provide a meaningful incentive to Shareholders to participate in the Rights Offering. Upon completion of the Rights Offering and assuming all Rights are exercised, the Company will have 19,333,976 Shares outstanding, of which the Shares issued under the Rights Offering represent 50%, assuming no Warrants issued pursuant to the Rights Offering are exercised.
It is expected that the Rights will trade on the CSE under the symbol “AGN.RT” commencing on or about March 28, 2023 and will trade until 9:00 a.m. (Pacific time) on or about April 27, 2023. The Rights will expire at 2:00 p.m. (the “Expiry Time”) on April 27, 2023 (the “Expiry Date”), after which time unexercised Rights will be void and of no value. Shareholders who fully exercise their Rights under the basic subscription privilege will be entitled to subscribe for additional Units, if available, as a result of unexercised Rights prior to the Expiry Time on the Expiry Date, subject to certain limitations as set out in the Company’s Rights Offering circular dated March 21, 2023 (the “Circular”), which will be filed on SEDAR under Algernon’s profile at www.sedar.com, along with the Notice of Rights Offering on form 45-106F14 (the “Notice”). The Notice and the Rights DRS advice/subscription will be mailed to Shareholders in the Eligible Jurisdictions as of the Record Date on or about April 5, 2023. The Company expects to close the Rights Offering on or before May 3, 2023.
The Rights will be offered to Shareholders resident in all provinces and territories of Canada (the “Eligible Jurisdictions”).
Registered Shareholders in the Eligible Jurisdictions who wish to exercise their Rights must forward the completed subscription form, together with the applicable funds, to the rights agent, TSX Trust Company (the “Rights Agent”), on or before the Expiry Time on the Expiry Date. Shareholders who own their Shares through an intermediary, such as a bank, trust company, securities dealer, or broker, will receive materials and instructions from their intermediary.
Subject to the detailed provisions of the Circular, Rights certificates or DRS advises and subscription forms will not be mailed to Shareholders resident outside of the Eligible Jurisdictions, unless such Shareholders are able to establish to the satisfaction of the Company that they are eligible to participate in the Rights Offering, and provide such evidence to the Company and the Rights Agent by April 20, 2023. After April 20, 2023, the Rights Agent will attempt, on a commercially reasonable basis, to sell the Rights of ineligible Shareholders (other than those Shareholders from whom the Company accepts subscriptions) over the facilities of the CSE. The Rights Agent will mail cheques representing the net proceeds, without interest, from such sales, to such ineligible Shareholders. The Company believes that its directors and senior officers who own Shares intend to exercise the majority of their Rights to purchase Units under their basic subscription privilege; however, the number of approximate Rights that will exercised by directors and senior officers cannot be ascertained as at this date.
AlphaNorth Asset Management an “insider” (as such term is defined under applicable securities laws) and holder of greater than 10% of the issued and outstanding Shares of the Company, has advised the Company that it intends to exercise, subject to relevant restrictions, its basic subscription privilege to acquire 1,268,040 Units for total gross proceeds to the Company of $317,010.
The Company has also entered into an agreement with Research Capital Corporation (“RCC” or the “Soliciting Dealer”) pursuant to which RCC has been appointed as the exclusive soliciting dealer for and on behalf of the Company on a commercially reasonable efforts basis. RCC will also have the right, but not the obligation, to purchase up to $500,000 of Units for which subscriptions have not been received by the Expiry Time on the Expiry Date (the “Top-up Right”). RCC will receive a commission of five percent of the gross proceeds of the Rights Offering, excluding those Rights exercised by Shareholders on the president’s list (the “President’s List”) for which a commission of two percent will be paid to a maximum of 25% of the gross proceeds of the Rights Offering. RCC will also receive that number of Soliciting Dealer warrants (the “Soliciting Dealer Warrants”) equal to five percent of the Units subscribed for under the Rights Offering, excluding those Units subscribed for by Shareholders on the President’s List for which they will receive two percent in Soliciting Dealer Warrants and those Units resulting from the exercise of the Top-up Right. Additionally, the Soliciting Dealer will receive that number of Soliciting Dealer Warrants equal to eight percent of the Units issued under the exercise of the Top-up Right. Each Soliciting Dealer Warrant entitles the holder thereof to purchase one Unit at the Unit subscription price, for a period of 18 months from the date of issuance. The Company will also pay to RCC a corporate finance fee of $20,000 plus tax.
The proceeds of the Rights Offering are expected to be used for working capital and general corporate purposes and administrative expenses.
The Rights and the underlying Shares and Warrants, and the Shares issuable upon exercise of the Warrants, have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the any U.S. state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities within the United States, and the securities may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States or any U.S. person, unless registered under the U.S. Securities Act and applicable U.S. state securities laws, or pursuant to an exemption from such registration requirements described in the Circular. There shall be no offer or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful absent registration or qualification of such securities under the laws of any such jurisdiction. In addition, Warrants may not be exercised by, or for the account of benefit of, any person in the United States or any U.S. person absent an exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.
About Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for IPF with chronic cough, and chronic kidney disease, and is the parent company of a newly created private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Launch-of-Rights-Offering?id=393908
TWEET from CEO Hans
Update: $medh => $daze PT1
— the 1 & Only HANS (@The1OnlyHans) March 20, 2023
Good and bad news
Bad news. Still waiting. FINRA requested a long list of docs from our TA. Rep at FINRA quit!!! Left us and our application in limbo. GOOD NEWS! Our legal team and our TA are getting this done!! HOW EVER LONG IT TAKES!!
Outstanding 9,653,656 on 3/13/2023 with Filing
https://webfiles.thecse.com/1._Algernon_-_Confirmation_of_Mailing_to_CSE_re_Forward_share_split_-_March_2023.pdf?TZVYRIuUBa63F7r3DFb1gPR1PNTxkEsg
Reverse 1 from 2 shares held then another 1 from 100 shares held - so call it 200 is only 1 share before the forward
Then this forward split make’s it 50 gone for every 1 share one still now holds
High of .41 $AGNPF before any split is now
cost of $20.50
Or Down 97.5% to $0.5125 now
JMO
Outstanding: 9,653,724 following a 4 to 1 forward split Date: March 6, 2023
https://webfiles.thecse.com/2._Algernon_-_CSE_Form_7_-_February_2023.pdf?Bd5.qDF.eds0r2w5R33.3oHzvzfejK9z
Outstanding: 114,144,104 for March 5, 2023
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_Mar_5_2023.pdf?71z75itZ20xA5PowQTWUD8nhiFSZ2eF1
Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-Appoints-Global-TBI-Expert-and-Former-NFL-Neurological-Player-Care-Safety-Director-Dr-David-Brody-?id=391937
Outstanding Shares 690,499,016 posted 03/01/2023
https://www.otcmarkets.com/stock/MEDH/security
Announces 4 for 1 Forward Share Split
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-4-for-1-Forward-Share-Split?id=391638
Victor Lazzaro, Jr. was @ the start of Disaboom which was in 2007 which is now $MEDH but named Changed to DAZED, Inc with Wyoming but waiting finea change and hopefully $DAZE for a Symbol
Back to Victor Lazzaro, Jr started in 2007 and was 61 then and is now 77 years old and probably done with $MEDH (JMO)
https://www.otcmarkets.com/filing/html?id=5053841&guid=624-kqGn-e2DB3h
The Tony he brings up is not tied to $MEDH and probably a Grandson - If @ all connected to $MeDH
He did @ 3:13 PM · Feb 21, 2023
You'd love that!! Gahdam right I'm still here! When it happens it happens. I see you rooting then hating. Pick a side. Cheers!
— the 1 & Only HANS (@The1OnlyHans) February 21, 2023
Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-Initiates-Traumatic-Brain-Injury-Research-Program-With-DMT-Appoints-Global-TBI-Expert-as-Advisor?id=390557
Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-Provides-Update-on-Phase-1-DMT-Clinical-Study-Drug-Found-Safe-to-Proceed-to-Next-Phase?id=390177
Outstanding 2,413,431 for February 6, 2023
Monthly 5th Report for January
https://webfiles.thecse.com/1._Algernon_-_CSE_Form_7_-_January_2023.pdf?3kUC9WvT0YmqegXPIjuMasYRDKg32eGY
Outstanding: 114,144,104 for February 5, 2023
Monthly 5th Report
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_Feb_5_2023.pdf?gv.bqxGWqLhlPeTsv4R_JkdRRQYDQABP
Outstanding Shares 690,499,016 posted 02/01/2023
https://www.otcmarkets.com/stock/MEDH/security
New LazyDaze location - 1812 Eubank - Abq, New Mexico
https://earth.google.com/web/search/1812+Eubank+Boulevard+Northeast,+Albuquerque,+New+Mexico/@35.10248687,-106.53285543,1670.08276367a,0d,81.72798317y,77.1614894h,91.01428853t,0r/data=CigiJgokCWe9uI_rREJAEfyyyFGMREJAGYN-WEgGb1fAIctCaK8hb1fAIhoKFkhLUUd2U0c5WEppRnJDTUdpcjRGWlEQAg
What a busy Beaver - here is a blog
https://www.smartbranddigital.com/blog
Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Appoints-Dr-Peter-Dicpinigaitis-to-Chronic-Cough-Advisory-Board?id=385978
Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Plans-for-a-180-Patient-Phase-2b-Chronic-Cough-Study-of-Ifenprodil?id=385637
Outstanding 2,385,332 on January 6, 2023
Monthly 5th Report
https://webfiles.thecse.com/12._Algernon_-_CSE_Form_7_-_December.pdf?UFu4qXqknrhPcZp.6AKCBUUjuH6YETV.